文献速递角膜与眼表疾病白内障与屈光手术

新型角膜嵌体的3年随访研究:临床结果与结局

A 3-year follow-up study of a new corneal inlay: clinical results and outcomes.
PubMed 文献 · Br J Ophthalmol · 2019-08-24

本研究对31只老视眼植入Flexivue Microlens角膜嵌体后随访3年,30只眼完成随访。3年时76.9%的患眼裸眼近视力提高至Jaeger 1(1年时为87.1%),73.3%的患者报告近视力良好或极好(1年时为90.3%)。作者结论认为该嵌体改善了近视力,但长期可能发生可控的并发症。

要点

  • 3年随访时76.9%的患眼裸眼近视力提高至Jaeger 1,低于1年随访时的87.1%。
  • 73.3%的患者报告近视力良好或极好,低于1年随访时的90.3%。
  • 3例因近距和远距视物模糊取出嵌体,1例术后20个月发生浅层角膜溃疡,2例行白内障摘除,4例行嵌体更换。

核心结论

  • Presbia Flexivue Microlens通过改善近视力为老视提供了治疗。
  • 长期可能发生可控的并发症。

研究设计与样本

  • 对31只老视患者非主导眼进行Flexivue Microlens角膜嵌体植入的3年随访分析。
  • 使用飞秒激光制作300 μm深度的基质囊袋后植入嵌体。
  • 随访内容包括屈光、眼前节成像分析(Oculyser)、光学质量分析(OPD-Scan)、单眼和双眼裸眼及矫正视力、对比敏感度(明视和暗视)、满意度问卷和不良事件报告。
  • 3年随访时检查了30只眼。

主要发现

  • 3年随访时76.9%的患眼裸眼近视力提高至Jaeger 1(1年随访时为87.1%)。
  • 73.3%的患者报告近视力良好或极好(第一年时为90.3%)。
  • 裸眼远视力随时间保持稳定。
  • 除4例取出嵌体的患者外,所有眼在所有随访中视力提高四行。
  • 3例因近距和远距视物模糊取出嵌体;1例术后20个月发生浅层角膜溃疡;2例行白内障摘除;4例行嵌体更换以增加近视力矫正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Here, we report the results of a 3-year follow-up analysis of the outcomes of the Flexivue Microlens corneal inlay. PATIENTS: Non-dominant eyes (n=31) of emmetropic presbyopic patients (spherical equivalent: -0.5 to 1.00 dioptre). METHODS: A Flexivue Microlens corneal inlay was implanted after the creation of a 300 μm deep stromal pocket using a femtosecond laser. Patients were followed up according to a clinical protocol involving refraction, anterior segment imaging analysis (Oculyser), optical quality analysis (OPD-Scan), monocular binocular uncorrected and corrected visual acuity tests, contrast sensitivity measurements (photopic and mesopic), satisfaction questionnaire results and adverse event reporting. RESULTS: Thirty patients were examined at the 3-year follow-up in this ongoing study. The mean uncorrected near visual acuity improved to Jaeger 1 in 76.9% of eyes treated with the inlays (vs 87.1% at the 1-year follow-up). All eyes improved four lines in all visits, except for four patients for whom the inlay was explanted. Patients reported that their near vision was good or excellent in 73.3% of cases (vs 90.3% in the first year). The UDVA remained stable over time. Three patients were explanted due to blurred vision for near-point and far-point distances. One patient developed a superficial corneal ulcer after 20 months. Two patients underwent cataract removal. Four patients underwent inlay exchange to increase near power correction. CONCLUSIONS: The Presbia Flexivue Microlens provided presbyopia treatment by improving near vision. Manageable complications may occur over the long term. CLINICAL TRIAL REGISTRATION NUMBER: U1111-1185-5684 and 0310451200000550.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Beer SMC, Werner L, Nakano EM, et al. A 3-year follow-up study of a new corneal inlay: clinical results and outcomes. Br J Ophthalmol. 2019. PMID: 31446390. doi:10.1136/bjophthalmol-2019-314314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。